See more : Medley Management Inc. (MDLM) Income Statement Analysis – Financial Results
Complete financial analysis of Avidity Biosciences, Inc. (RNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avidity Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shibaura Electronics Co.,Ltd. (6957.T) Income Statement Analysis – Financial Results
- Liberta Co.,Ltd. (4935.T) Income Statement Analysis – Financial Results
- Energisa S.A. (ENGI11.SA) Income Statement Analysis – Financial Results
- PT Nusa Konstruksi Enjiniring Tbk (DGIK.JK) Income Statement Analysis – Financial Results
- BioPlus Acquisition Corp. (BIOSU) Income Statement Analysis – Financial Results
Avidity Biosciences, Inc. (RNA)
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379.00K |
| Cost of Revenue | 2.10M | 1.39M | 639.00K | 37.60M | 14.54M | 8.44M |
| Gross Profit | 7.46M | 7.84M | 8.69M | -30.82M | -12.22M | -8.06M |
| Gross Profit Ratio | 78.02% | 84.96% | 93.15% | -454.03% | -526.95% | -2,125.86% |
| Research & Development | 190.97M | 150.40M | 101.18M | 37.60M | 14.54M | 8.44M |
| General & Administrative | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Other Expenses | 0.00 | 4.92M | 42.00K | -78.00K | 0.00 | 0.00 |
| Operating Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Cost & Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Interest Income | 23.97M | 4.98M | 104.00K | 206.00K | 7.39M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 209.00K | 7.39M | 718.00K |
| Depreciation & Amortization | 2.10M | 1.39M | 639.00K | 373.00K | 597.00K | 383.00K |
| EBITDA | -233.50M | -177.53M | -117.41M | -43.77M | -16.75M | -10.12M |
| EBITDA Ratio | -2,442.44% | -1,939.65% | -1,265.83% | -652.38% | -732.38% | -2,668.87% |
| Operating Income | -235.60M | -178.91M | -118.05M | -44.28M | -17.33M | -10.50M |
| Operating Income Ratio | -2,464.41% | -1,939.65% | -1,265.83% | -652.38% | -747.39% | -2,769.92% |
| Total Other Income/Expenses | 23.38M | 4.92M | 42.00K | -78.00K | -7.40M | -718.00K |
| Income Before Tax | -212.22M | -174.00M | -118.01M | -44.36M | -24.73M | -11.22M |
| Income Before Tax Ratio | -2,219.87% | -1,886.33% | -1,265.38% | -653.53% | -1,066.58% | -2,959.37% |
| Income Tax Expense | 0.00 | -4.92M | -639.00K | -373.00K | 7.39M | 718.00K |
| Net Income | -212.22M | -169.08M | -117.37M | -43.98M | -32.12M | -11.93M |
| Net Income Ratio | -2,219.87% | -1,833.01% | -1,258.52% | -648.03% | -1,385.12% | -3,148.81% |
| EPS | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EPS Diluted | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| Weighted Avg Shares Out | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Weighted Avg Shares Out (Dil) | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
Top-notch biotech stock Avidity collapsed Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences Honors Rare Disease Day®
SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day®, highlighting the...
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellington Management, as well as multiple large investment management firms Pro forma cash, cash equivalents...
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.88 per share a year ago.
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the...
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2024, the Human Capital Management Committee...
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Jan. 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2024, the Human Capital Management Committee...
Source: https://incomestatements.info
Category: Stock Reports